Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gilead Sciences Trading Down 0.7%
GILD traded down $1.18 during trading on Friday, hitting $156.19. 7,762,254 shares of the stock were exchanged, compared to its average volume of 6,823,515. The firm has a 50 day simple moving average of $146.73 and a 200 day simple moving average of $137.15. The firm has a market cap of $193.67 billion, a price-to-earnings ratio of -58.50 and a beta of 0.31. Gilead Sciences, Inc. has a 1 year low of $114.02 and a 1 year high of $160.51. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same period in the previous year, the company posted $2.01 EPS. Gilead Sciences’s revenue was up 10.6% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post -0.47 EPS for the current year.
Gilead Sciences Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were paid a dividend of $0.82 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the stock. Bank of Nova Scotia acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth $100,056,000. Groupe la Francaise grew its stake in Gilead Sciences by 30.9% during the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock worth $6,270,000 after buying an additional 11,712 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Gilead Sciences during the 2nd quarter worth $55,754,000. Baird Financial Group Inc. grew its stake in Gilead Sciences by 3.6% during the 2nd quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after buying an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new position in Gilead Sciences during the 2nd quarter valued at about $6,251,000. 83.67% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several analysts recently weighed in on GILD shares. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Zacks Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Needham & Company LLC reiterated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Finally, Truist Financial raised their target price on shares of Gilead Sciences from $150.00 to $158.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $159.33.
Get Our Latest Analysis on GILD
Key Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Oncology pipeline strengthened: Gilead agreed to collaborate with Vir Biotechnology on next-generation T-cell engagers (TCEs) for solid tumors. Gilead will receive exclusive development and commercialization rights, while Vir contributes its immunology and antibody-engineering platform. The agreement covers three potential cancer therapies and could provide Vir up to approximately $1.74 billion in milestone payments, or about $1.9 billion including other deal components. The partnership gives Gilead access to a potentially important cancer-treatment technology and complements its earlier investment in TCEs through the acquisition of Ouro Medicines. Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
- Positive Sentiment: Defensive-sector rotation: Investors have been shifting toward large pharmaceutical companies as a technology-stock selloff increases demand for companies viewed as more defensive. Gilead, along with other major drugmakers, has been trading near record levels, helping reinforce positive momentum and investor interest. Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
- Neutral Sentiment: Analyst sentiment remains mixed: Recent coverage highlights conflicting views on Gilead’s prospects. Increased searches and investor attention may support trading activity, but the reports do not identify a clear consensus change in earnings expectations or price targets. Analysts Have Conflicting Sentiments on These Healthcare Companies
- Negative Sentiment: Valuation and technical risks: With GILD near its recent highs, the stock may be vulnerable to profit-taking if the broader defensive rotation fades or if investors question the long-term commercial potential of the early-stage TCE programs. The partnership also entails milestone payments that depend on successful development.
About Gilead Sciences
Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.
Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.
Featured Stories
- Five stocks we like better than Gilead Sciences
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
